Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Track down Your Optimal Conservative Vehicle: Famous Brands to Consider - 2A Past filled with Old Civilizations: The World's Most established Societies
- 3Vote in favor of your Favored Kind of Scarf
- 4Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- 5Must-Have Wellness Gear: What to Purchase for Successful Exercises
- Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- The Job of a Land Legal counselor in Property Exchanges
- 4 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- 2025 Was Another Exceptionally Hot Year
- 3D Printers for Specialists
- Best Exciting ride: Which One Rushes You the Most?
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
